Research Analysts Offer Predictions for DFTX Q2 Earnings

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Investment analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Definium Therapeutics in a report released on Wednesday, May 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.51) per share for the quarter, down from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Definium Therapeutics’ current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for Definium Therapeutics’ Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.10) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.35) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($1.22) EPS.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23).

A number of other equities analysts have also commented on the company. Oppenheimer restated an “outperform” rating and set a $40.00 price objective on shares of Definium Therapeutics in a research note on Thursday, April 23rd. Piper Sandler restated an “overweight” rating and issued a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a research report on Friday, May 8th. Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 16th. Leerink Partners upped their price objective on shares of Definium Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Finally, Jefferies Financial Group assumed coverage on shares of Definium Therapeutics in a research note on Thursday, January 29th. They set a “buy” rating and a $30.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $37.92.

Definium Therapeutics Trading Down 3.0%

Shares of DFTX stock opened at $21.35 on Friday. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.13 billion, a P/E ratio of -8.57 and a beta of 2.37. The stock has a 50 day simple moving average of $20.39 and a 200 day simple moving average of $16.36. Definium Therapeutics has a 1 year low of $6.28 and a 1 year high of $26.25.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DFTX. Royal Bank of Canada raised its holdings in shares of Definium Therapeutics by 10.4% during the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after buying an additional 6,148 shares in the last quarter. Creative Planning boosted its stake in Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after buying an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. grew its position in Definium Therapeutics by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after acquiring an additional 2,342 shares during the last quarter. Rhumbline Advisers grew its position in Definium Therapeutics by 6.3% in the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after acquiring an additional 6,839 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after acquiring an additional 2,003 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.